Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
11,005,257
-
Shares change
-
-1,229,588
-
Total reported value, excl. options
-
$474,739,581
-
Value change
-
-$55,155,873
-
Put/Call ratio
-
92%
-
Number of buys
-
66
-
Number of sells
-
-47
-
Price
-
$43.16
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2021
145 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2021.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11,005,257 shares
.
Largest 10 shareholders include FMR LLC (2,229,843 shares), STATE STREET CORP (1,275,906 shares), BlackRock Inc. (1,054,104 shares), Artemis Investment Management LLP (1,031,864 shares), ALLIANCEBERNSTEIN L.P. (815,881 shares), VANGUARD GROUP INC (789,439 shares), Logos Global Management LP (400,000 shares), First Light Asset Management, LLC (358,439 shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (288,605 shares), and GEODE CAPITAL MANAGEMENT, LLC (252,640 shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.